Caras W E, Pluss J L
Department of Medicine, Pulmonary Disease/Critical Care Service, Fitzsimons Army Medical Center, Aurora, Colorada, USA.
Mayo Clin Proc. 1996 Jan;71(1):25-30. doi: 10.4065/71.1.25.
To characterize chronic necrotizing pulmonary aspergillosis (CNPA) clinically, radio-graphically, and pathologically and to describe its response to treatment.
We present three cases of well-documented CNPA and detail the long-term clinical and pathologic responses to the new antifungal triazole, itraconazole.
Although all three patients had an appreciable clinical response to itraconazole therapy, tissue obtained at the time of operation or autopsy revealed residual CNPA despite 5 to 12 months of treatment. Even though pathologic resolution of the CNPA did not occur, patient prognosis was determined solely by comorbid illness.
Itraconazole seems to be effective in CNPA when used in a suppressive (rather than curative) role in patients with limited life expectancy.
从临床、影像学及病理学方面对慢性坏死性肺曲霉病（CNPA）进行特征描述，并阐述其对治疗的反应。
我们报告3例记录完整的CNPA病例，并详细说明新型抗真菌三唑类药物伊曲康唑的长期临床及病理反应。
尽管所有3例患者接受伊曲康唑治疗后临床反应明显，但手术或尸检时获取的组织显示，即便经过5至12个月的治疗，仍存在残留的CNPA。尽管CNPA未在病理上得到缓解，但患者的预后仅由合并症决定。
对于预期寿命有限的患者，伊曲康唑用于抑制（而非治愈）CNPA时似乎有效。
